abciximab (ReoPro)

03/01/2012 - "IC abciximab in the setting of pPCI for ST-segment elevation myocardial infarction may be beneficial for patients with higher risk profiles."
12/01/2011 - "Furthermore, early abciximab administration was associated with a significant improvement in pre-procedural thrombolysis in myocardial infarction (TIMI) 3 flow (21.6% vs. 10.1%, P < 0.0001), post-procedural TIMI 3 flow (90% vs. 84.8%, P = 0.04), an improvement in myocardial perfusion as evaluated by post-procedural myocardial blush grade (MBG) 3 (52.0% vs. 43.2%, P = 0.03) and ST-segment resolution (58.4% vs. 43.5%, P < 0.0001) and significantly less distal embolization (10.1% vs. 16.2%, P = 0.02). "
11/01/2006 - "There was also a numerical but not statistically significant reduction in myocardial infarction rate using abciximab bolus-only compared with placebo. "
06/01/1999 - "A successful therapy is presented using the antiplatelet agent abciximab, alone, in an ST-segment elevation acute myocardial infarction. "
01/01/2012 - "Efficacy of clotinab in acute myocardial infarction trial-ST elevation myocardial infarction (ECLAT-STEMI)."

03/01/2014 - "The INFUSE-AMI trial randomized 452 patients with anterior STEMI to intracoronary bolus abciximab vs. no abciximab, and to thrombus aspiration vs. no aspiration. "
10/01/2013 - "Previous studies failed to assess the individual prognostic role of thrombus aspiration (TA) or abciximab in primary percutaneous coronary intervention (pPCI), due their prevalent combined use. "
05/01/2009 - "This study investigated the relationship between abciximab treatment and presence of LV thrombus in the first few days after primary stenting. "
12/01/2008 - "This study evaluates risk factors for thrombus formation and assesses the efficacy and safety of abciximab for clot dissolution. "
12/01/2000 - "This is considerably less than the 80% level of receptor inhibition that has been proposed to prevent coronary thrombus formation in animal models and that has been achieved in clinical trials with abciximab. "

06/01/2012 - "As compared to IV route, IC abciximab was associated with a significant improvement in myocardial perfusion (OR [95% CI]=1.76 [1.28-2.42], p<0.001), without significant benefits in terms of mortality (OR [95% CI]=0.85 [0.59-1.23], p=0.39), reinfarction (OR [95% CI]=0.79 [0.46-1.33], p=0.37), or major bleeding complications (OR [95% CI]=1.19 [0.76-1.87], p=0.44). "
01/01/2012 - "The present meta-analysis showed that IC administration of abciximab is associated with significant benefits in mortality at short-term follow-up compared to IV abciximab administration, without any excess of major bleeding in STEMI patients undergoing PPCI. "
08/01/2003 - "Although abciximab increases the risk of bleeding in all patients, the increase in relative risk is not significantly greater in patients with CRI. "
10/01/2008 - "Abciximab thought to be safe and effective in initial case series and early trials, has not been shown to improve outcomes in AIS, and is associated with higher rates of hemorrhage. "
06/01/2010 - "This meta-analysis shows that early administration of smGPIs is as effective as abciximab in the setting of PPCI for STEMI, without an increase in bleeding complications."

04/01/2012 - "Acute coronary syndromes: Is early abciximab beneficial in STEMI?"
11/07/2006 - "In patients with non-ST-elevation acute coronary syndromes undergoing PCI, the efficacy of abciximab appears to be age-dependent, with greater benefit among younger patients."
11/07/2006 - "No studies have specifically performed an age-based analysis of the efficacy of abciximab in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention (PCI). "
06/01/2010 - "Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis."
09/30/2013 - "Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: a meta-analysis of clinical trials."

04/01/2005 - "This study was performed to obtain more information about the safety and potential efficacy of abciximab in patients with stroke. "
01/01/2008 - "A previous randomized, placebo-controlled, double-blind study suggested that abciximab may be safe and effective in treatment of acute ischemic stroke. "
04/27/2000 - "Further research is needed to determine the safety and potential efficacy of abciximab for treatment of ischemic stroke."
01/01/2008 - "This trial did not demonstrate either safety or efficacy of intravenous administration of abciximab for the treatment of patients with acute ischemic stroke regardless of end point or population studied. "
12/01/2008 - "We elected to test the safety and possible efficacy of abciximab in treatment of enrolled subjects with wake-up stroke. "